EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The N‐Acetyltransferase 2 Polymorphism and Susceptibility to Inflammatory Bowel Disease: A Case–Control Study

Pawel Petryszyn iD, Grzegorz Zurakowski, Robert Dudkowiak, Marta Machowska, Agnieszka Gruca, Pawel Ekk-Cierniakowski, Jadwiga Skretkowicz, Elzbieta Poniewierka, Anna Wiela-Hojenska, Krystyna Glowacka

Pharmacology Research & Perspectives · 2025

DOI: 10.1002/prp2.70040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Pawel Petryszyn und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Wroclaw Medical University, Wroclaw, Poland. Hauptthemen laut MEDLINE: Arylamine N-Acetyltransferase, Genetic Predisposition to Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The enzyme N‐acetyltransferase 2 (NAT2) plays an important role in metabolism and detoxification of xenobiotics, including carcinogens and medications. We aimed to assess the contribution of the NAT2 polymorphism to susceptibility to inflammatory bowel disease (IBD) in the Polish population. The study involved 101 IBD patients and 100 healthy controls. The NAT2 gene mutations at positions 481T, 803G, 590A, and 857A were identified using the polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP) technique on peripheral blood DNA samples. Carriers of the NAT2*5 allele had a greater chance of developing Crohn's disease (CD) (OR = 1.73, 95% CI 1.06–2.83). Also, the NAT2*4/5 genotype was more prevalent in CD patients (OR = 2.77, 95% CI 1.17–6.57). When compared to the control group, the prevalence of the NAT2*4/6 genotype in the IBD patient population was significantly lower (10.9% vs. 30.0%, p < 0.01). In the Polish population, polymorphism in the NAT2 gene may potentially alter susceptibility to IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arylamine N-AcetyltransferaseGenetic Predisposition to DiseaseHumansCase-Control StudiesMaleFemaleAdultPolandMiddle AgedCrohn DiseaseInflammatory Bowel DiseasesGenotypePolymorphism, GeneticYoung Adult

Stichwörter der Autor:innen

Crohn diseaseacetyltransferasesgenetic polymorphisminflammatory bowel diseasessulfasalazine

Substanzen

Arylamine N-AcetyltransferaseNAT2 protein, human

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Wroclaw Medical University, Wroclaw, Poland.
  • Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland.
  • Department of Gastroenterology and Internal Medicine, University Clinical Center of the Medical University of Warsaw, Warszawa, Poland.
  • Warsaw School of Economics, Warszawa, Poland.
  • Calisia University, Kalisz, Poland.

ORCID-Profile: Pawel Petryszyn

Förderung

  • Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu

Zitieren

APA

Petryszyn, P., Zurakowski, G., Dudkowiak, R., Machowska, M., Gruca, A., Ekk-Cierniakowski, P., Skretkowicz, J., Poniewierka, E., Wiela-Hojenska, A., & Glowacka, K. (2025). The N‐Acetyltransferase 2 Polymorphism and Susceptibility to Inflammatory Bowel Disease: A Case–Control Study. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70040

Vancouver

Petryszyn P, Zurakowski G, Dudkowiak R, Machowska M, Gruca A, Ekk-Cierniakowski P, et al. The N‐Acetyltransferase 2 Polymorphism and Susceptibility to Inflammatory Bowel Disease: A Case–Control Study. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70040

BibTeX
@article{Petryszyn2025,
  author = {Petryszyn, Pawel and Zurakowski, Grzegorz and Dudkowiak, Robert and Machowska, Marta and Gruca, Agnieszka and Ekk-Cierniakowski, Pawel and Skretkowicz, Jadwiga and Poniewierka, Elzbieta and Wiela-Hojenska, Anna and Glowacka, Krystyna},
  title = {The N‐Acetyltransferase 2 Polymorphism and Susceptibility to Inflammatory Bowel Disease: A Case–Control Study},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  doi = {10.1002/prp2.70040}
}
Kostenlos starten →